Download Report

EMERGING BIOTECH
SOLUTIONS
Your Success is Our Business
Covance has serviced over 500 biotech companies in the past 2 years and managed more than
1,800 unique molecules and nearly 200 IND/CTA submissions in the last 5 years. We are
the only global drug development partner with expertise spanning preclinical, clinical and
commercial phases.
Through our previous partnerships with biotech companies, Covance has gained insights
into the special challenges you face. That’s why we’ve developed this new initiative specifically
designed for Emerging Biotech companies that helps you save time and money while
maintaining study quality and data integrity. Our client-centric approach includes:
▶ A dedicated team, with therapeutic expertise, focused on development from study concept
through execution and final reporting
▶ A drug development approach that minimizes risk and maximizes opportunities
▶ Flexible processes and simplified financial options
DISCOVERY
RESEARCH
DEVELOPMENT
PRECLINICAL
PHASE I
PHASE II
COMMERCIALIZATION
PHASE III
Individual Milestone Solutions
Lead
Optimization
IND/CTA
Enabling
FIH
POC
Covance MarketPlace
Early Phase Development Solutions
Lead Optimization through POC
IND/CTA through POC
Full Development Solutions
Lead Optimization through Phase IV
Phase III-IV
PHASE IV
Tailored Solutions to Optimize Your
Probability of Success
Covance generates more drug development data for the regulatory evaluation of efficacy and safety
than any other company in the world. Only Covance has the global infrastructure and industryleading nonclinical, regulatory and clinical expertise to deliver a tightly aligned continuous
solution to bridge the journey across key development milestones. That’s why we are the preferred
partner of both pharmaceutical and biotech companies at every stage of development.1
PRECLINICAL
▶LEAD OPTIMIZATION
Covance has experience in finding solutions to common causes in drug development
delays during both the nonclinical and clinical stages of the process. We often encourage pursuing many angles at once to evaluate which option minimizes
risk and maximizes efficiency.
PHASE I
▶ EARLY PHASE DEVELOPMENT SOLUTIONS
Covance provides one consistent and dedicated molecule solution team with a single
point of contact to advance your program from nonclinical through First-in-Human,
Phase II and Proof of Concept phases.
PHASE II
▶ COVANCE COMPLETE PoC
Covance can help you demonstrate both the clinical and economic aspects of
development to maximize your asset’s value. We combine perspectives in safety, efficacy, quality and commercial potential to quickly reach decision points and
increase ROI.
PHASE III
▶ LATE STAGE CLINICAL DEVELOPMENT
Covance provides a dedicated management team to help navigate the complexities of
development such as simplifying trial protocols, optimizing the selection of trial site
location, improving trial technology and processes, and receiving
guidance from our global regulatory experts.
▶ CENTRAL LABORATORY SERVICES
Covance extends your reach with the most experienced
central lab in the industry. You can tap into our vast
clinical expertise around the globe, including staff
pathologists, a dedicated scientific team and
experienced project management to meet your
study’s financial and timeline milestones.
▶ COVANCE MARKETPLACE
No matter what phase you are in, Covance provides an
exchange for you to forge the right connection with
potential investors, while safeguarding your asset.
1
Source: Robert W. Baird & Co. survey data
Your ideal partner for the specific needs of emerging biotech companies.
Contact your account executive to learn more, or visit www.covance.com.
Covance Inc., headquartered in Princeton, NJ, is the drug development business of Laboratory
Corporation of America® Holdings (LabCorp®). Covance is the marketing name for Covance Inc.
and its subsidiaries around the world.
The Americas + 1.888.COVANCE + 1.609.452.4440
Europe / Africa + 00.800.2682.2682 Asia Pacific + 800.6568.3000
© Copyright 2015 Covance Inc. SSCDS054-0215